KD033 shows promise in tumor models
NEW YORK—Kadmon Holdings Inc. debuted preclinical data at the Society for Immunotherapy of Cancer’s Annual Meeting regarding KD033, an anti-PD-L1/IL-15 fusion protein being developed for the treatment of cancer. Among the findings were data showing that the compound inhibited tumor growth in several in-vivo syngeneic tumor models, and demonstrated dose-dependent efficacy in a syngeneic mouse model of resistant melanoma. KD033 was capable of engendering a strong immune memory response after one treatment, with treated mice remaining tumor-free even after tumor re-challenges. When combined with anti-PD1 therapy, KD033 showed synergistic activity. The immunotherapy consists of IL-15 fused to an anti-PD-L1 antibody, which serves to guide IL-15 activity directly to the tumor microenvironment.